Adenocarcinoma of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity results showed that, the Pd(II) complex of L has higher anti-tumor effect than L and its Pt(II) complex against the tested human breast adenocarcinoma (MCF-7), human prostate adenocarcinoma (LNCAP), and human colon carcinoma (LS174T) cell lines.
|
29216566 |
2018 |
Heartburn
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Adsorption parameters of Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub>@PT towards Au(III) and Pd(II) including initial pH, reaction time, initial concentration of metal ions, effect of acidity and interference of coexisting metal ions were investigated.
|
30447562 |
2019 |
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
Muscle Rigidity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
By using the steric hindrance of the nonplanar linker, the connectivity of Zr<sub>6</sub> node can be tuned from 8-c to unusual 4-c. Further, through either one-pot synthesis or postsynthetic linker installation strategies, the connectivity of Zr<sub>6</sub> node can be tuned from 8-c to 10-c by the insertion of a secondary linear dicarboxylate linker, from which not only the temperature-dependent flexibility of the structure can be effectively controlled with enhanced rigidity and thermal stability but also a scaffold for postsynthetic metalation of Pd(II) catalyst for Heck coupling reaction is offered.
|
31497944 |
2019 |
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The <b>C</b><sub>iq</sub> cage was completely decomposed into free <b>L</b><sub>iq</sub> and [Pd(Cl)<sub>4</sub>]<sup>2-</sup> within 1 h. However, the <b>C</b><sub>q</sub> cage was more long lived and was only fully decomposed after 7 h. The new ligands (<b>L</b><sub>iq</sub> and <b>L</b><sub>q</sub>) and the Pd(II) cage architectures (<b>C</b><sub>iq</sub> and <b>C</b><sub>q</sub>) were assessed for their cytotoxic properties against two cancerous cell lines (A549 lung cancer and MDA-MB-231 breast cancer) and one non-cancerous cell line (HDFa skin cells).
|
30525025 |
2018 |
Zika Virus Infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
PAF1 was shown to play opposite roles in JEV and ZIKV infections.
|
31199156 |
2019 |
Peroxisomal Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Per6p has significant overall sequence similarity with the human peroxisome assembly factor PAF-1, a protein that is defective in certain patients suffering from the peroxisomal disorder Zellweger syndrome, and with car1, a protein required for peroxisome biogenesis and caryogamy in the filamentous fungus Podospora anserina.
|
8628321 |
1996 |
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis.
|
29217648 |
2018 |
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The <b>C</b><sub>iq</sub> cage was completely decomposed into free <b>L</b><sub>iq</sub> and [Pd(Cl)<sub>4</sub>]<sup>2-</sup> within 1 h. However, the <b>C</b><sub>q</sub> cage was more long lived and was only fully decomposed after 7 h. The new ligands (<b>L</b><sub>iq</sub> and <b>L</b><sub>q</sub>) and the Pd(II) cage architectures (<b>C</b><sub>iq</sub> and <b>C</b><sub>q</sub>) were assessed for their cytotoxic properties against two cancerous cell lines (A549 lung cancer and MDA-MB-231 breast cancer) and one non-cancerous cell line (HDFa skin cells).
|
30525025 |
2018 |
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity results showed that, the Pd(II) complex of L has higher anti-tumor effect than L and its Pt(II) complex against the tested human breast adenocarcinoma (MCF-7), human prostate adenocarcinoma (LNCAP), and human colon carcinoma (LS174T) cell lines.
|
29216566 |
2018 |
Breast adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity results showed that, the Pd(II) complex of L has higher anti-tumor effect than L and its Pt(II) complex against the tested human breast adenocarcinoma (MCF-7), human prostate adenocarcinoma (LNCAP), and human colon carcinoma (LS174T) cell lines.
|
29216566 |
2018 |
Enzyme inhibition disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In this work, the synthesis, crystal structure, characterization, and enzyme inhibition effects of the novel a series of 2-aminopyridine liganded Pd(II) N-heterocyclic carbene (NHC) complexes were examined.
|
31374523 |
2019 |
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that hPaf1/PD2 is overexpressed in OCSCs and maintains the self-renewal of OCSCs through its interaction with OCT3/4; thus, hPaf1/PD2 may be a potential therapeutic target to overcome tumor relapse in OC.
|
28122356 |
2017 |
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that hPaf1/PD2 is overexpressed in OCSCs and maintains the self-renewal of OCSCs through its interaction with OCT3/4; thus, hPaf1/PD2 may be a potential therapeutic target to overcome tumor relapse in OC.
|
28122356 |
2017 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Canertinib combined with Pd(II) complex leads to inhibition of migration and invasion.
|
30825616 |
2019 |
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
The <b>C</b><sub>iq</sub> cage was completely decomposed into free <b>L</b><sub>iq</sub> and [Pd(Cl)<sub>4</sub>]<sup>2-</sup> within 1 h. However, the <b>C</b><sub>q</sub> cage was more long lived and was only fully decomposed after 7 h. The new ligands (<b>L</b><sub>iq</sub> and <b>L</b><sub>q</sub>) and the Pd(II) cage architectures (<b>C</b><sub>iq</sub> and <b>C</b><sub>q</sub>) were assessed for their cytotoxic properties against two cancerous cell lines (A549 lung cancer and MDA-MB-231 breast cancer) and one non-cancerous cell line (HDFa skin cells).
|
30525025 |
2018 |
Peroxisome biogenesis disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The first, functional complementation, was established as a viable approach by Fujiki and colleagues, who identified PAF-1, the first known peroxisome biogenesis disorder gene.
|
8993569 |
1996 |
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The free salen ligand and its Pd(II) complexes have also been tested against human hepatoma cancer cell line (Huh7) and results manifested exceptional anti-proliferative effects of the Pd(II) complexes.
|
22858862 |
2012 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Simian Immunodeficiency Viruses and HIV-2 are also restricted in PAF1 expressing cells.
|
22082156 |
2011 |
MIXED LINEAGE LEUKEMIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
YEATS mutations induced a gain of function, transforming primary hematopoietic cells in vitro and in transplantation assays through aberrant transcription and H2B ubiquitination of <i>Hoxa9</i> and <i>Meis1</i> Mechanistically, H3 and PAF1 competed for ENL interaction, with activating mutations favoring PAF1 binding, whereas the MLL moiety provided a constitutive PAF1 tether allowing MLL fusions to circumvent H3 competition.
|
29217648 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results indicate that hPaf1/PD2 is overexpressed in OCSCs and maintains the self-renewal of OCSCs through its interaction with OCT3/4; thus, hPaf1/PD2 may be a potential therapeutic target to overcome tumor relapse in OC.
|
28122356 |
2017 |
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, the results suggest that the new designed Pt(II) and Pd(II) complexes are well promising candidates for use in cancer treatment, particularly for human colorectal cancer.Communicated by Ramaswamy H. Sarma.
|
30146941 |
2019 |
Pancreatic carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
|
22046413 |
2011 |
Malignant neoplasm of pancreas
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
|
22046413 |
2011 |
Leukemia, Myelocytic, Acute
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of <i>Hoxa9</i> and <i>Meis1</i> in acute myeloid leukemia.
|
29774127 |
2018 |